Introduction
Since the acquired immune deficiency syndrome (AIDS) was recognised in the United States of America in 1981, it has spread to Western Europe. The first case of AIDS in the Netherlands was diagnosed in 1982. ' AIDS is probably caused by a retrovirus, which was first described by Barre-Sinoussi et al in 1983 as lymphadenopathy associated virus (LAV)2 and later by Gallo et al as human T lymphotropic virus type III (HTLV-III). 3 We investigated the introduction of LAV/HTLV-III into the Netherlands by studying a cohort of 685 homosexual men who had participated in a hepatitis B vaccine efficacy study (in 1980-2) for the presence of antibodies to LAV/HTLV-III. The primary reason for the study was to rule out the possible transmission of LAV/HTLV-III by the hepatitis B vaccine, derived from heat inactivated plasma.
Patients, materials, and methods
STUDY POPULATION
The study population consisted of homosexual men who participated in a placebo controlled efficacy trial of a heat inactivated hepatitis B vaccine. 4 The plasma used for the preparation of this vaccine was collected before 1977 from unpaid blood donors who were hepatitis B surface antigen (HBsAg) positive. The vaccine trial started in November 1980, participants could enter it until 31 December 1981, and follow up continued until the end of 1982. Subjects entered the trial if they were aged between 16 and 50 years, were negative for hepatitis B virus markers, had a serum alanine transferase activity of less than 50 IU/l (normal activity less than 21 IU/1), had no serious illness, and had had at least two different male sexual partners in the six months before the intake. For the LAV/HTLV-III study we selected men from the vaccine study who lived in and around Amsterdam.
CONDUCT OF THE STUDY
At entry into the vaccine study (month 0) the participants were asked some questions concerning Introduction of LA V/HTL V-III into the male homosexual community in Amsterdam their medical history and lifestyle. Age Table I shows the characteristics of the 685 homosexual men who participated in this study. Their mean (SD) age was 30 1 (7) years and the mean duration of their homosexual activity 11 (7) years, 240 (35%) had had more than 10 different sexual partners in the six preceding months, 128 (18&7%) had a history of syphilis, and 506 (73 9%) of anal sexual contact (active or passive was not specified). On entry to the study, none of the 685 men had antibodies to HBV (339 (49-5%) had received hepatitis B vaccine, and 346 (50 5%) placebo), 281 (41%) had antibodies to HAV, and 486 (71%) had antibodies to CMV. In previous studies the end point attack rate for HBV was 18& 3% in men receiving placebo,4 for HAV was 14% in susceptible men,5 and for CMV was 27-3% in seronegative men.6 Of the 20 participants with antibodies to LAV/HTLV-III, 19 (95%) also had antibodies to CMV, whereas of the 665 men with no antibodies to LAV/HTLV-III, 469 (70 5%) had antibodies to CMV, a significant difference (X2 = 4 54; 005 >p > 002).
CLINICAL SYMPTOMS OF LAV/HTLV-III INFECTIONS
Six of 15 men who seroconverted reported a mononucleosis like illness with malaise and fever, sometimes combined with lymphadenopathy, sore throat, and cough. Two of these six men gave positive results for HBsAg in the same period as the LAV/HTLV-III seroconversion, whereas another participant had had a preceding reinfection with CMV. CONCURRENT There has been concern about the possible transmission of AIDS by the plasma derived hepatitis B vaccines. Many of the HBsAg positive carriers from whose plasma these vaccines were prepared were homosexual men, and therefore at 1gah risk of AIDS. The plasma used for the preparation of the heat inactivated (at 103°C for 90 seconds and 65°C for 10 hours) HBV vaccine used in this study, was collected before 1977, before LAV/HTLV-III was introduced into the homosexual community in the Netherlands, according to this study. The plasma pool was therefore unlikely to have contained LAV/HTLV-III. Moreover, heat has been shown to inactivate LAV/HTLV-III completely.7 The study published here proves that the HBV vaccine used did not transmit LAV/HTLV-III, as the percentage of seroconversions among the vaccine recipients (2-1%) was found to be the same as in those receiving placebos (2-3%).
Of the lifestyle characteristics of the homosexual men participating in this study, only anal sexual contact appeared to be correlated with seropositivity or seroconversion for LAV/HTLV-III, as was also found in a recent Danish study.8 Anal sexual contact is a well known risk factor for two other sexually transmitted diseases in homosexual men: hepatitis B9 '°and CMV.6 LAV/HTLV-III has been found in semen," 12 and entrance of the virus is likely to be facilitated by damage to the mucosa, which is known to occur during anal sexual intercourse. The correlation between antibodies to CMV and to LAV/HTLV-III also points to the importance of anal sexual contact in transmission. As the number of seropositive men in this analysis was small compare-d with the number of seropositive men, the influence of other factors in the transmission of LAV/HTLV-III cannot be ruled out.
In a recent article Cooper et al described a mononucleosis like illness in 11 of 12 homosexual men who underwent LAV-HTLV-III seroconversion. '3 This does not correspond with the findings of our study, in which only a minority of men who seroconverted mentioned any symptoms and some of the men with symptoms had double infections, which made it impossible to identify the cause of the clinical signs. A reason for the discrepancy could be that patients in the Australian study (who were seen every six months) were interviewed again after the seroconversion was detected. The knowledge of the seroconversion may have biased the interviewers, as nothing is mentioned about control retrospective interviews of subjects without a seroconversion. An alternative explanation is that in our study the participants (who were seen at least every three months) simply forgot to mention their symptoms, which may have been of short duration and of minor importance.
From the clinical data we conclude that the incubation period of AIDS in homosexual men can be at least three years after servoconversion, and that during that period most people do not have any clinical symptoms.
In conclusion, our study shows clearly that the introduction of LAV/HTLV-III in the Dutch male homosexual community took place at the end of the 'seventies, a few years before the first diagnosis of AIDS in a native Dutchman, which supports the existing evidence that LAV-HTLV-III is the cause of AIDS.
